Delivery Order SPE2DB22D3019-SPE2DB25FK4FH
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $2,418.33 for 90 tablets of Losartan-HCTZ 50-12.5 mg, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $18,928.44 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $1,683.45 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in quantities of 90. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded procurement. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 29, 2025. This award represents a routine...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $3,436.44 firm fixed-price delivery order contract (SPE2DX15D3015|SPE2DX24F0EN0) to AmerisourceBergen Drug Corp for the supply of 4,563,434,205 units of Losartan-HCTZ 50-12.5 mg tablets. This delivery order is part of a larger $999,999,999 indefinite delivery contract (IDC) held by AmerisourceBergen with the DLA, which provides a comprehensive range of pharmaceutical products and medical supplies to support military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies, specifically Losartan-HCTZ 50-12.5 mg tablets (90-count), valued at $2,297.83 with a firm fixed price structure. The award, issued on August 1, 2025, is set to complete by August 4, 2025. This is a non-set-aside competitive award with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a $19,748.97 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a quantity of 90 units. The contract employs firm fixed-price pricing with no set-aside designation and is scheduled for completion by July 28, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is...
- The Defense Logistics Agency awarded a delivery order valued at $24,691.64 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-25 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $3,843.81 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets in quantities of 90 units. This contract employs firm fixed price terms and carries an ultimate completion date of September 16, 2025. The award was made competitively with no set-aside designation, and performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a $2,162.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Losartan-HCTZ 50-12.5 mg tablets (90-count supply) on August 7, 2025, with a completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $22,817.18 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-25 mg tablets (90-count) under a firm fixed-price contract. The award was made on August 29, 2025, with an ultimate completion date of September 2, 2025, and the product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This delivery order is...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB25FK4FHDelivery Order
The Defense Logistics Agency awarded a $14,962.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90-tablet supplies of Losartan-HCTZ 100-12.5 mg tablets, with performance in Conshohocken, Pennsylvania and completion by September 15, 2025. This non-set-aside award was competitively procured and represents a routine pharmaceutical supply delivery under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, holds a significant $999.99 billion indefinite delivery/indefinite quantity contract (SPE2DX) with DLA Troop Support Medical through December 2026, which serves as the umbrella agreement enabling this delivery order. This prime IDQ contract provides comprehensive global pharmaceutical support across multiple therapeutic domains for military healthcare systems, including medications, vaccines, and medical supplies. The current award for Losartan-HCTZ—a common antihypertensive medication—reflects the company's ongoing role as a critical vendor supplying essential medications to support Defense Health Agency and other federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0k | 9/12/25 |